topotecan has been researched along with Dermatitis Medicamentosa in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aydin, F; Canturk, T; Senturk, N; Turanli, AY; Yanik, F; Yildiz, L | 1 |
| Fels, C; Hau, P; Janssen, G; Liebeskind, AK; Peters, O; Sauerbrey, A; Suttorp, M; Wagner, S; Wolff, JE | 1 |
1 trial(s) available for topotecan and Dermatitis Medicamentosa
| Article | Year |
|---|---|
Pegylated-liposomal doxorubicin and oral topotecan in eight children with relapsed high-grade malignant brain tumors.
Topics: Administration, Oral; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma; Child; Child, Preschool; Choroid Plexus Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Drug Eruptions; Glioblastoma; Hematologic Diseases; Humans; Neoplasm Recurrence, Local; Polyethylene Glycols; Recurrence; Retrospective Studies; Stomatitis; Topotecan; Treatment Outcome | 2008 |
1 other study(ies) available for topotecan and Dermatitis Medicamentosa
| Article | Year |
|---|---|
Topotecan-induced celluitis-like fixed drug eruption.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Cellulitis; Chemotherapy, Adjuvant; Cystadenocarcinoma, Serous; Dose-Response Relationship, Drug; Drug Eruptions; Fatal Outcome; Female; Humans; Hysterectomy; Infusions, Intravenous; Leg Dermatoses; Ovarian Neoplasms; Ovariectomy; Risk Assessment; Topotecan | 2002 |